BR0113312A - Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes - Google Patents

Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Info

Publication number
BR0113312A
BR0113312A BR0113312-8A BR0113312A BR0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A BR 0113312 A BR0113312 A BR 0113312A
Authority
BR
Brazil
Prior art keywords
compounds
type
composition
tetrazole
diabetes
Prior art date
Application number
BR0113312-8A
Other languages
English (en)
Portuguese (pt)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0113312A publication Critical patent/BR0113312A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0113312-8A 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes BR0113312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
PCT/EP2001/009207 WO2002014312A1 (en) 2000-08-15 2001-08-09 Tetrazolyl-phenyl acetamide glucokinase activators

Publications (1)

Publication Number Publication Date
BR0113312A true BR0113312A (pt) 2003-07-01

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113312-8A BR0113312A (pt) 2000-08-15 2001-08-09 Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes

Country Status (20)

Country Link
US (3) US6369232B1 (enExample)
EP (1) EP1311504B1 (enExample)
JP (1) JP3961948B2 (enExample)
KR (1) KR100518061B1 (enExample)
CN (1) CN1209362C (enExample)
AR (1) AR031718A1 (enExample)
AT (1) ATE297921T1 (enExample)
AU (2) AU2001283998B2 (enExample)
BR (1) BR0113312A (enExample)
CA (1) CA2419416C (enExample)
DE (1) DE60111540T2 (enExample)
DK (1) DK1311504T3 (enExample)
ES (1) ES2243541T3 (enExample)
MX (1) MXPA03001275A (enExample)
PA (1) PA8525201A1 (enExample)
PE (1) PE20020386A1 (enExample)
PT (1) PT1311504E (enExample)
UY (1) UY26885A1 (enExample)
WO (1) WO2002014312A1 (enExample)
ZA (1) ZA200300904B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
JP2006509774A (ja) * 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト 2型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換(チアゾール−2−イル)−アミドまたはスルホンアミド
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1737870A1 (en) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CN1960995B (zh) * 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
RU2420525C2 (ru) * 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
US7994339B2 (en) * 2005-12-15 2011-08-09 Nihon Nohyaku Co., Ltd. Phthalamide derivative, agricultural or horticultural pesticide, and use of the pesticide
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8008332B2 (en) * 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008084872A1 (ja) 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CA2700783C (en) * 2007-10-08 2015-03-17 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
AU2009205070A1 (en) * 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
MY163114A (en) 2008-04-28 2017-08-15 Kyorin Seiyaku Kk Cyclopentylacrylamide derivative
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
EP0968209A1 (en) * 1997-01-28 2000-01-05 Merck & Co., Inc. THIAZOLE BENZENESULFONAMIDES AS $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
HRP20010688B1 (en) * 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators

Also Published As

Publication number Publication date
JP3961948B2 (ja) 2007-08-22
DE60111540T2 (de) 2006-03-16
DK1311504T3 (da) 2005-10-17
PA8525201A1 (es) 2002-07-30
AU8399801A (en) 2002-02-25
DE60111540D1 (de) 2005-07-21
ATE297921T1 (de) 2005-07-15
PT1311504E (pt) 2005-10-31
CA2419416C (en) 2009-10-13
US20020065275A1 (en) 2002-05-30
AR031718A1 (es) 2003-10-01
KR100518061B1 (ko) 2005-09-28
CA2419416A1 (en) 2002-02-21
EP1311504B1 (en) 2005-06-15
US6441180B1 (en) 2002-08-27
US20020035266A1 (en) 2002-03-21
CN1466584A (zh) 2004-01-07
MXPA03001275A (es) 2003-06-30
ZA200300904B (en) 2004-04-30
UY26885A1 (es) 2002-02-28
ES2243541T3 (es) 2005-12-01
AU2001283998B2 (en) 2005-10-20
US20020035267A1 (en) 2002-03-21
CN1209362C (zh) 2005-07-06
KR20030022408A (ko) 2003-03-15
US6369232B1 (en) 2002-04-09
JP2004506632A (ja) 2004-03-04
EP1311504A1 (en) 2003-05-21
WO2002014312A1 (en) 2002-02-21
PE20020386A1 (es) 2002-05-13
US6388088B1 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
BR0113312A (pt) Tetrazol, composição farmacêutica que compreende o mesmo, processo para a preparação dessa composição, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii, processo para a preparação de um tetrazol e compostos resultantes
BR0110492A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0212775B8 (pt) composto de 1,2,4-triazol e medicamento
BR0114708A (pt) Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição
NO20033385D0 (no) Fuserte heterocykliske forbindelser
BR0208126A (pt) Conjugados de ingrediente ativo de has
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
PE20061357A1 (es) COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
WO2000063208B1 (en) Substituted imidazoles, their preparation and use
BR0110704A (pt) Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0309964A (pt) Derivados anticonvulsivos de sulfamoto substituìdo
CO5690638A2 (es) Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
ATE556067T1 (de) Modulatoren des vanilloid rezeptors
UY28528A1 (es) Nuevos compuestos
ATE457971T1 (de) Derivate von 4-hydroxybutansäure und deren höheren homologen als liganden von g- hydroxybutyrat- (gbh-)rezeptoren, pharmazeutische zusammensetzungen, die diese enthalten, und pharmazeutische anwendungen
DE60221348D1 (de) Substituierte chinoline zur behandlung von durch protozoen und retroviren verursachten co-infektionen
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
MXPA05013772A (es) 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4.
WO2006126939A8 (en) Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.